Explore ›
Finding
Finding
decline
Eighteen of 78 (23.1%) pediatric cancer survivors at low risk for hearing loss failed behavioral hearing screening at 1000-8000 Hz, substantially higher than the approximately 10% failure rate documented in the general pediatric population.
| Effect size | 23.1% |
| CI | 95% CI: 14-34% |
| Comparator | Historical general pediatric population hearing screening failure rate of approximately 10% |
| Effect summary | decline; 23.1%; CI: 95% CI: 14-34% |
| Effect modifiers | [{"modifier": "gender", "interaction_p": "not significant", "direction": "null", "stratum_details": "", "plain_language": "Boys and girls failed at similar rates", "annotation_notes": ""}, {"modifier": "race", "interaction_p": "not significant", "direction": "null", "stratum_details": "", "plain_language": "Race did not predict screening failure", "annotation_notes": ""}, {"modifier": "cancer diagnosis type", "interaction_p": "not significant", "direction": "null", "stratum_details": "", "plain_language": "Leukemia, sarcoma, Wilms tumor, and lymphoma patients all had similar failure rates", "annotation_notes": ""}, {"modifier": "intrathecal chemotherapy", "interaction_p": "not significant", "direction": "null", "stratum_details": "51/78 (65.4%) received intrathecal chemotherapy", "plain_language": "Receiving intrathecal chemotherapy did not increase screening failure risk", "annotation_notes": ""}, {"modifier": "radiation treatment (non-cranial)", "interaction_p": "not significant", "direction": "null", "stratum_details": "8/78 (10.3%) received radiation", "plain_language": "Non-cranial radiation did not increase screening failure risk", "annotation_notes": ""}, {"modifier": "ototoxic agent exposure (furosemide, gentamicin)", "interaction_p": "not significant", "direction": "null", "stratum_details": "15/78 (19%) received furosemide or gentamicin", "plain_language": "Exposure to furosemide or gentamicin during cancer treatment did not predict screening failure", "annotation_notes": ""}, {"modifier": "time from diagnosis", "interaction_p": "not significant", "direction": "null", "stratum_details": "Failures: median 7.8 years (Q1-Q3: 4-11.2); Passes: median 5.7 years (Q1-Q3: 4-8.7)", "plain_language": "Patients who failed tended to be further from diagnosis, but this was not statistically significant", "annotation_notes": "Trend toward longer time from diagnosis in failures, but not statistically significant."}, {"modifier": "time from end of treatment", "interaction_p": "not significant", "direction": "null", "stratum_details": "Failures: median 6.4 years (Q1-Q3: 2.2-9.5); Passes: median 3 years (Q1-Q3: 2.3-7)", "plain_language": "Patients who failed tended to be further from end of treatment, but this was not statistically significant", "annotation_notes": "Trend toward longer time from treatment in failures, but not statistically significant."}] |
Connected entities
Interventions
Conditions
Outcomes
Populations
Source
PMC8712396
PREVALENCE OF HEARING SCREENING FAILURES IN LOW-RISK CHILDHOOD CANCER SURVIVORS